New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease

Reviews in Gastroenterological Disorders

Volumn 5, Issue 1, 2005, Pages 10-18

  Sandborn, William J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Anti tumor necrosis factor agents; Crohn's disease; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; ETANERCEPT; GAMMA INTERFERON; HYDROCORTISONE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G4; INFLIXIMAB; INTERLEUKIN 12; MERCAPTOPURINE; METHOTREXATE; ONERCEPT; PLACEBO; PREDNISONE; PROTEIN P55; PROTEIN P75; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; GASTROINTESTINAL AGENT; HYBRID PROTEIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; RECOMBINANT HUMAN TUMOR NECROSIS FACTOR BINDING PROTEIN 1; RECOMBINANT HUMAN TUMOR NECROSIS FACTOR-BINDING PROTEIN-1; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR DECOY RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ACUTE INFUSION REACTION; ANAPHYLAXIS; ARTHRALGIA; ASPERGILLOSIS; AUTOIMMUNE DISEASE; BACKACHE; BLEEDING; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CROHN DISEASE; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DEMYELINATION; DRUG BINDING SITE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG MECHANISM; DRUG TOLERABILITY; DYSPNEA; EDEMA; ENTERITIS; ENZYME INHIBITION; ERYTHEMA; FEVER; FLUSHING; HEADACHE; HEART FAILURE; HEART PALPITATION; HISTOPLASMOSIS; HUMAN; HYPOTENSION; IMMUNOGENICITY; IMMUNOPATHOLOGY; INJECTION PAIN; INJECTION SITE REACTION; LEUKOCYTOSIS; LISTERIOSIS; LUPUS VULGARIS; MILIARY TUBERCULOSIS; MUSCLE SPASM; MYALGIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRURITUS; REVIEW; SEPSIS; SERUM SICKNESS; SIDE EFFECT; TH1 CELL; THORAX PAIN; ULCERATIVE COLITIS; URTICARIA; DRUG ANTAGONISM;

ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOGLOBULIN G; INFLAMMATORY BOWEL DISEASES; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR DECOY RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 14844334633     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis. 1999;5:285-294.
2. Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut. 1991;32:913-917.
3. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut. 1993;34: 1705-1709.
4. Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992:339:89-91.
5. Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut. 1997;40:443-448.
6. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
7. Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut. 2004;53:1366-1373.
8. Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 2001;121:1145-1157.
9. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002;50:206-211.
10. van den Brande JMH, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003;124:1774-1785.
11. Shen C, Maerten P, Van Assche G, et al. A fully human anti-TNF mAb adalimumab (D2E7) induces caspase-dependent apoptosis of human peripheral blood monocytes and T cells. Gastroenterology. 2004;126(suppl 2):A-153.
12. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
13. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359: 1541-1549.
14. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-413.
15. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350: 876-885.
16. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001;7:83-88.
17. Ochsenkuhn T, Sackmann M, Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol. 2004;16:1167-1171.
18. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis. A randomised placebo controlled trial. Gut. 2004;53(suppl VI):A223.
19. Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52:998-1002.
20. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117:761-769.
21. Remicade infliximab for IV injection. Prescribing information. 1998. Available at http://www.remicade.com.
22. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-553.
23. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
24. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology. 2003; 124:917-924.
25. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315-1324.
26. Hanauer S, Rutgeerts P, Targan S, et al. Delayed hypersensitivity to infliximab (Remicade) reinfusion after a 2-4 year interval without treatment. Gastroenterology. 1999;116:A731.
27. Remicade [package insert]. Malvern, PA: Centocor; 2004.
28. Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology. 2003;125:32-39.
29. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44: 2862-2869.
30. Thomas CW Jr., Weinshenker BG, Sandborn WJ. Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis. 2004;10:28-31.
31. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002;46:3151-3158.
32. Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003;138:807-811.
33. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha- neutralizing agent. N Engl J Med. 2001;345:1098-1104.
34. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002;46:2565-2570.
35. Velayos FS, Sandborn WJ. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis. 2004;10: 1657-1660.
36. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol. 2002;97: 2962-2972.
37. Mow WS, Abreu-Martin MT, Papadakis KA, et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol. 2004;2:309-313.
38. Hanauer S, Lukas M, MacIntosh D, et al. A randomized, double-blind, placebo-controlled trial of the human anti-TNF-α monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease. Gastroenterology. 2004;127:332.
39. Sandborn WJ, Hanauer S, Loftus EV, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004;99:1984-1989.
40. Youdim A, Vasiliauskas EA, Targan SR, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis. 2004;10:333-338.
41. Humira [package insert]. Abbott Park, IL: Abbott Laboratories; 2004.
42. Schreiber S, Rutgeerts P, Fedorak R, et al., and the CDP870 Crohn's Disease Study Group. CDP870, a humanized anti-TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003;124:A-61.
43. Winter T, Wright J, Ghosh S, et al. Intravenous CDP870, a humanized anti-TNF antibody fragment, in patients with active Crohn's disease - an exploratory study. Gastroenterology. 2003;124: A-377.
44. Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet. 1997;349:521-524.
45. Sandborn WJ, Feagan BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology. 2001;120:1330-1338.
46. Sandborn WJ, Feagan BG, Radford-Smith G, et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double-blind, placebo-controlled trial. Gut. 2004;53:1485-1493.
47. Feagan BG, Sandborn WJ, Baker J, et al. A randomized, double-blind, placebo-controlled, multicenter trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease. Gastroenterology. 2000;118:A655.
48. Celltech announces results from CDP 571 Phase III studies in Crohn's disease [press release]. Berkshire, UK: Celltech Group plc; July 30, 2002.
49. Hanauer S, Present D, Targan SR, et al. CDP571, a humanized monoclonal antibody to TNF-α, is well tolerated in Crohn's disease patients with previous hypersensitivity to infliximab. Gastroenterology. 2003;124:A-517.
50. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088-1094.
51. Amgen Inc. Data on file.
52. Rutgeerts P, Lemmens L, Van Assche G, et al. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther. 2003;17:185-192.
53. Rutgeerts P, Fedorak RN, Rachmilevich D, et al., and the Onercept Study Group T. Onercept (recombinant human p55 tumour necrosis factor receptor) treatment in patients with active Crohn's disease: randomized, placebo-controlled, dose-finding phase II study. Gut. 2004;53(suppl VI):A47.